Teva Pharmaceutical Indus Q2 Adj. EPS $0.02 Misses $0.25 Estimate, Sales $4.142B Beat $4.047B Estimate
Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.25 by 92 percent. This is a 96.97 percent decrease over earnings of $0.66 per share
Teva made less money per share than experts predicted, even though the company sold more products than expected. When a company misses on profits but beats on sales, it means their costs got really high, so watch whether they can fix that problem.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.